Trial Profile
A study to evaluate the effectiveness of Brentuximab vedotin in patients with transplant naive relapsed/refractory Hodgkin Lymphoma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Nov 2017
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 17 Nov 2017 New trial record
- 01 Nov 2017 Results published in the British Journal of Haematology.